OSE Immuno

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation

09 Dec 2025 01:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development

08 Dec 2025 01:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer

17 Nov 2025 12:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines

07 Nov 2025 12:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports First Half 2025 Financial Results

15 Oct 2025 13:00:22 بحسب Nasdaq GlobeNewswire

Appointment of Marc Le Bozec as Interim CEO

03 Oct 2025 02:00:00 بحسب Nasdaq GlobeNewswire

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors

30 Sep 2025 13:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy

26 Sep 2025 01:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

25 Sep 2025 12:00:00 بحسب Nasdaq GlobeNewswire

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital

24 Sep 2025 02:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court

23 Sep 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting

22 Sep 2025 02:00:00 بحسب Nasdaq GlobeNewswire

Update on Information Relating to the General Meeting of September 30, 2025

12 Sep 2025 02:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer

11 Sep 2025 12:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025

09 Sep 2025 14:30:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025

08 Sep 2025 12:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation

04 Sep 2025 12:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation

04 Sep 2025 12:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM

29 Aug 2025 02:00:00 بحسب Nasdaq GlobeNewswire

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting

25 Aug 2025 01:00:00 بحسب Nasdaq GlobeNewswire